

**BESTINVER** 

Velázquez 140 28006 Madrid. España Tel. +34 / 91 566 24 00 Fax. Tel. +34 / 91 566 24 50

THIS COMMUNICATION IS NOT FOR THE DIRECT OR INDIRECT, TOTAL OR PARTIAL, RELEASE, DISTRIBUTION OR PUBLICATION, IN THE UNITED STATES OF AMERICA (INCLUDING THE TERRITORIES AND POSSESSIONS, ANY OF THE STATES OF THE UNITED STATES AND DISTRICT OF COLUMBIA), AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE OFFER MENTIONED MAY CONSTITUTE A BREACH OF ITS LEGISLATION.

## **INSIDE INFORMATION NOTICE**

## Accelerated placement of shares of Laboratorios Farmacéuticos Rovi, S.A.

Madrid, March 14th, 2022

Bestinver S.V, S.A. (Sociedad Unipersonal) ("Bestinver" or the "Placement Entity"), in compliance with the provisions of Article 17 of Regulation (EU) No. 596/2014 on market abuse and Article 226 of the revised text of the Securities Market Law, approved by Royal Legislative Decree 4/2015, of October 23, and concordant provisions, hereby notifies the *Comisión Nacional del Mercado de Valores* (the Spanish National Securities Market Commission) of the following inside information:

Bestinver is carrying out on behalf of Norbel Inversiones, S.L., (the "Seller") a private placement exclusively addressed to qualified investors (the "Placement") of a package of up to 2.803.448 shares (the "Shares") of Laboratorios Farmacéuticos Rovi, S.L., ("Rovi"), representing approximately 5% of its capital stock.

### **Placement characteristics**

The Placement will be carried out through a procedure known as "accelerated bookbuilding" and is expected to last no more than one day.

The will of the Seller, which is and will continue to be the major shareholder of Rovi, is to continue increasing the liquidity of the security taking into account the redemption of own shares in the scope of the buy-back programmes announced by Rovi. The Seller has committed with the Placement Entity to maintain a Lock Up of its remaining interest for a period of 180 days.

The process of the Placement will commence immediately and during this period, the Placement Entity will develop activities of dissemination and promotion of the Placement in order to obtain indications of interest or proposals of acquisition of the Shares by potential investors.

### Placement Result

Once the Placement process has been completed, the Placement Entity will inform the market in a timely manner of the result of the Placement through the publication of the corresponding inside information communication. The expected date of settlement of the Placement is March 17<sup>th</sup>, 2022.

Yours faithfully,

Bestinver SV S.A.



**BESTINVER** 

Velázquez 140 28006 Madrid. España Tel. +34 / 91 566 24 00 Fax. Tel. +34 / 91 566 24 50

THIS COMMUNICATION IS NOT FOR DIRECT OR INDIRECT, TOTAL OR PARTIAL, RELEASE, DISTRIBUTION OR PUBLICATION IN THE UNITED STATES OF AMERICA (INCLUDING THE TERRITORIES AND POSSESSIONS, ANY OF THE STATES OF THE UNITED STATES AND DISTRICT OF COLUMBIA), AUSTRALIA, CANADA OR JAPAN, OR IN ANY OTHER JURISDICTION IN WHICH THE OFFER MENTIONED MAY CONSTITUTE A BREACH OF ITS LEGISLATION.

# IMPORTANT INFORMATION

This document contains Inside Information according to the Regulation (EU) 596/2014 on Market Abuse.

This document is for information purposes only and does not intend to be complete, it is subject to changes and may not be released, published or distributed, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Canada, South Africa, Japan or in any other country or jurisdiction where the disclosure of this information may be restricted by law.

This communication does not constitute or contain an offer to sell nor an offer for the purchase of the securities in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Canada, South Africa, Japan, or in any other country or jurisdiction where the offer mentioned may constitute a breach of its legislation or in which de distribution of this information may be restricted by law. This communication is not a request of funds, securities or any other sort of compensation, and no compensation will be accepted as a response to this communication.

The securities herein referred to have not been and will not be registered under the U.S. Securities Act of 1933, as may be amended from time to time, or registered with the regulators of any state or jurisdiction of the United States. Accordingly, the Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, or application of an exemption of registration, according to the U.S. Securities Act of 1933, or in any other country or jurisdiction without prior compliance with the applicable legislation. There will be no public offering of securities in the United States or in any other country or jurisdiction.

No prospectus or offering document has been or will be prepared in connection with the information referred to in this document. Any investment decision in connection with the securities to which this document refers to must be made on the basis of publicly available information. Such information has not been independently verified. The information contained in this document is for background purposes only and does not purport to be full or complete.